IN8bio, Inc. (INAB)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about IN8bio, Inc. (INAB)
Company Performance

Current Price

as of Oct 16, 2024

$0.23

P/E Ratio

N/A

Market Cap

$10.71M

Description

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.

Metrics

Overview

  • HQNew York, NY
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerINAB
  • Price$0.2289-2.18%

Trading Information

  • Market Cap$10.71M
  • Float68.48%
  • Average Daily Volume (1m)363,536
  • Average Daily Volume (3m)304,547
  • EPS-$0.83

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$8.63M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$8.06M
  • EV$33.88M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B0.78
Documents
SEC Filings
8-K (2024-10-01)
8-K (2024-09-11)
8-K (2024-09-06)
8-K (2024-09-04)
8-K (2024-08-12)
8-K (2024-08-08)
8-K (2024-06-13)
8-K (2024-06-03)
8-K (2024-05-09)
8-K (2024-03-14)
8-K (2023-12-11)
8-K (2023-12-07)
8-K (2023-11-20)
8-K (2023-11-09)
8-K (2023-10-12)
8-K (2023-08-10)
8-K (2023-06-16)
8-K (2023-06-05)
8-K (2023-05-17)
8-K (2023-05-12)
8-K (2023-05-01)
8-K (2023-04-24)
8-K (2023-04-17)
8-K (2023-03-30)
8-K (2023-03-13)
8-K (2023-02-23)
8-K (2023-01-05)
10-Q (2024-08-08)
10-Q (2024-05-09)
10-Q (2023-11-09)
10-Q (2023-08-10)
10-Q (2023-05-12)
10-K (2024-03-14)
10-K (2023-03-30)
Factset Street Account
IN8bio to present new data from phase 1 trial of INB-100 at 2023 ASH annual meeting (2023-11-02T13:28:09Z)
IN8bio to present data highlighting potential of INB-200 and INB-400 to treat patients with newly diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting ($1.01, 0.00) (2023-11-10T12:07:04Z)
IN8bio reports Q3 EPS ($0.23) vs year-ago ($0.34) ($1.01, 0.00) (2023-11-09T21:40:21Z)
IN8bio presents data update from induced pluripotent stem cell (iPSC) platform at SITC 38th annual meeting ($1.03, +0.03) (2023-11-03T16:07:33Z)
IN8bio presents biologic correlative data from INB-200 phase 1 trial ($1.04, 0.00) (2023-11-06T13:13:49Z)
IN8bio completes dose escalation in Phase 1 trial of INB-100 for the treatment of Leukemias; initiates enrollment for Phase 2 trial of INB-400 in newly diagnosed Glioblastoma ($1.00, 0.00) (2023-10-12T12:08:59Z)
IN8bio announces presentation of data on INB-200 in newly diagnosed glioblastoma ($0.91, 0.00) (2023-11-20T12:07:05Z)